To include your compound in the COVID-19 Resource Center, submit it here.

Amgen sBLA gets Priority Review for Repatha CVOT data

FDA accepted and granted Priority Review to an sBLA from Amgen Inc. (NASDAQ:AMGN) for Repatha

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE